Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Stage not disclosed · ActiveModality: monoclonal antibody
Aliases GOHIBIC, Vilwaysi
Target C5a
Indications
Virally induced acute respiratory distress syndrome (ARDS)(Stage not disclosed)
Hidradenitis suppurativa (HS)(Stage not disclosed)
Chronic spontaneous urticaria (CSU)(Stage not disclosed)
Pyoderma gangrenosum (PG)(Stage not disclosed)
Status note Anti-C5a antibody (company's proprietary anti-C5a technology). Filing references a BLA submission for GOHIBIC (vilobelimab). No trial phases or stages are stated in the provided excerpts, which are largely forward-looking boilerplate; a potential partnership for vilobelimab in PG is under consideration.
Izicopan
Stage not disclosed · Active
Target C5aR1
Status note Named product candidate with future clinical trials referenced in the filing; a potential partnership of izicopan is under consideration. No modality, target, indication, or stage is stated in the provided excerpts.
Per-asset detail extracted from the 20-F filed 2026-03-20. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 4 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.